UCL Queen Square Institute of Neurology
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
TRIMTECH Therapeutics establishes Scientific Advisory Board
Alessio Ciulli has been appointed as Chair of the board
Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease
Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
GSK to explore link between Shingrix and dementia risk in new UK research collaboration
More than 55 million people worldwide are currently living with the neurodegenerative disease
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease
Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies
The neurodegenerative disease affects approximately 30,000 people in the US
Researchers develop new approach to target cells affected by motor neurone disease
The technique could lead to safer and more effective gene therapies for the neurodegenerative disease
Mayo Clinic explores AI and brain waves for neurodegenerative disease diagnosis
The team is using AI to assist in analysing routine EEGs for early identification of brain disorders